Acalabrutinib Regimens Improve PFS in Treatment-Na ïve Patients with CLL

Acalabrutinib alone and in combination with obinutuzumab significantly improved progression-free survival, compared with obinutuzumab plus chlorambucil in treatment-na ïve patients with chronic lymphocytic leukemia

Source: CancerNetwork - December 8, 2019 Category: Cancer & Oncology Authors: Gina Columbus Source Type: news